Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.73 USD

51.73
1,388,647

+0.47 (0.92%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $51.74 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Upbeat Q2 Results, FDA Nod to SNY & AZN RSV Antibody

FDA approves AstraZeneca (AZN) and Sanofi's (SNY) RSV antibody, Beyfortus. J&J (JNJ) and Novartis (NVS) announce strong second-quarter results.

Sanofi (SNY), AstraZeneca's RSV Antibody Gets FDA Nod in Infants

Following FDA approval, Sanofi (SNY)/AstraZeneca's (AZN) Beyfortus is the first RSV antibody approved to protect all infants. The companies plan to make it available ahead of the upcoming RSV season.

Microsoft (MSFT) Agrees to Keep Call of Duty on Sony PlayStation

Microsoft (MSFT) and Sony sign a deal to keep Call of Duty video game series on PlayStation consoles as its planned acquisition of Activision Blizzard appears closer to completion.

This is Why Sanofi (SNY) is a Great Dividend Stock

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.

Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?

Smart Beta ETF report for FVD

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Regeneron (REGN) Loses 13% in Three Months: What Lies Ahead?

Regeneron (REGN) declines 13% in the last three months due to regulatory setback for 8 mg dose strength of aflibercept and competition for lead drug.

Sanofi (SNY) Atopic Dermatitis Drug Meets Goals in Phase II Study

Sanofi's (SNY) phase II study, investigating amlitelimab for moderate-to-severe atopic dermatitis in adults, meets the primary endpoint.

Sanofi (SNY) Gains But Lags Market: What You Should Know

In the latest trading session, Sanofi (SNY) closed at $53.67, marking a +0.36% move from the previous day.

Sanofi (SNY) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.

Sanofi (SNY) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Sanofi (SNY) closed at $50.72, marking a +0.4% move from the previous day.

FDA Panel Endorses AstraZeneca (AZN), Sanofi's RSV Antibody

The FDA's AMDAC unanimously recommends AstraZeneca (AZN)/Sanofi's (SNY) nirsevimab as full immunization against RSV disease for all infants.

Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag

Innate (IPHA) and Sanofi's SAR'579 / IPH6101 get Fast Track Designation in the United States for the treatment of hematological malignancies.

Sanofi (SNY) Outpaces Stock Market Gains: What You Should Know

Sanofi (SNY) closed at $51.54 in the latest trading session, marking a +1.3% move from the prior day.

GSK's RSV Vaccine Arexvy Gets EU Approval for Older Adults

The approval of GSK's RSV vaccine for older adults is based on positive data from the pivotal AReSVi-006 phase III study.

Are You Looking for a High-Growth Dividend Stock?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.

Sanofi (SNY) Gains But Lags Market: What You Should Know

Sanofi (SNY) closed at $51.01 in the latest trading session, marking a +1.09% move from the prior day.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Okays PFE RSV Jab for Elderly, AZN Ends Brazikumab Studies

FDA approves Pfizer's (PFE) RSV vaccine for older adults and AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated metastatic castration-resistant prostate cancer

Pfizer's (PFE) RSV Vaccine for Older Adults Gets FDA Approval

The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for older adults, making it the second RSV vaccine to be approved by the regulatory agency.

The Zacks Analyst Blog Highlights Fomento Economico Mexicano, NextEra Energy, Sanofi, NVIDIA and Enbridge

Fomento Economico Mexicano, NextEra Energy, Sanofi, NVIDIA and Enbridge are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for FEMSA, NextEra Energy & Sanofi

Today's Research Daily features new research reports on 16 major stocks, including Fomento Economico Mexicano, S.A.B. de C.V. (FMX), NextEra Energy, Inc. (NEE) and Sanofi (SNY).

Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal

Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.

Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study

A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.

Regeneron (REGN) Faces Challenges as Eylea Sales Decline

Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.